{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-245852","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.620650+00:00","generated_at":"2026-05-17T02:44:06.676904+00:00","sec_items":["1.01","2.02","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alkermes to acquire Avadel for $18.50/share plus up to $1.50 CVR; $1.23B bridge financing arranged","bullets":["Cash consideration of $18.50 per Avadel share; CVR for additional $1.50 upon FDA approval of LUMRYZ and legal settlement.","Bridge term loan of up to $1.23B from JPMorgan to fund the cash consideration and fees; margin 3% SOFR + step-up.","Acquisition subject to Avadel shareholder vote, Irish High Court sanction, and US antitrust clearance; expected to close in Q1 2026.","Avadel equity awards to be canceled for cash and CVRs; stock options with exercise price ≥ $18.50 cancelled for no consideration.","Alkermes reported cash and total investments of $1.1B as of Sept 30, 2025 per investor presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-245852","json":"https://secwatch.observer/filing/0001193125-25-245852.json","markdown":"https://secwatch.observer/filing/0001193125-25-245852.md","text":"https://secwatch.observer/filing/0001193125-25-245852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/0001193125-25-245852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/d946576d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:44:06.676904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92b19b662e681112939559900212a10d5ca4bd32","claim":"Alkermes plc. incurred credit facility.","evidence_excerpt":"On the Agreement Date, Alkermes entered into the Bridge Credit Agreement as described under Item 1.01 above.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/0001193125-25-245852-index.htm","confidence":0.7,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}